Evidence map›Paper›PMID 40666811›Full record

ArticleFrontiers in microbiology2025

Xiaocong Li, Jiadong Chen, Chang Xu, Yong Li, Kun Li

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaocong LiHubei Three Gorges Polytechnic, Yichang, China.
Jiadong ChenCollege of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China.
Chang XuCollege of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China.
Yong LiHubei Three Gorges Polytechnic, Yichang, China.
Kun LiCollege of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Drug-induced liver injury is a common condition of therapeutics and requires solutions other than drugs. Dietary supplements and herbal products have beneficial potential against liver failure and are often associated with changes in intestinal flora. This study was designed to investigate Methods: The treatment group and model group were administered 0.5 mL of GC oil daily for 14 days, followed by induction of acute drug-induced liver injury using Acetaminophen (APAP) on the 15th day via intraperitoneal injection. Serum biochemical analysis and intestinal bacteria 16S rRNA sequencing were conducted to explore the anti-drug liver injury activity of GC. Results: The results showed that GC treatment alleviated the increased liver organ index caused by APAP. Furthermore, serum biochemical analysis revealed that GC therapy reduced alanine transaminase (ALT) and aspartate transaminase (AST) levels, indicating a protective effect against APAP-induced liver injury. Additionally, GC demonstrated the ability to regulate the diversity and composition of intestinal microbes and help increase the prevalence of beneficial microbes such as Discussion: Our findings indicate that GC plays a significant role in mitigating drug-induced liver injury by improving gut microbiome composition, reducing plasma ALT and AST levels, and inhibiting oxidative stress and inflammatory responses. The study further demands investigations to make pharmaceutical products to be used as nutraceuticals against drug-induced toxicities.

Indexed as

inflammationmetabolomicsmicemicrobiotaRhus chinensis Mill.

Identifiers

PMID40666811
PMCPMC12261674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.